Article Text
Abstract
Patients are increasingly turning to medical crowdfunding as a way to cover their healthcare costs. In the case of Charlie Gard, an infant born with encephalomyopathic mitochondrial DNA depletion syndrome, crowdfunding was used to finance experimental nucleoside therapy. Although this treatment was not provided in the end, we will argue that the success of the Gard family’s crowdfunding campaign reveals a number of potential ethical concerns. First, this case shows that crowdfunding can change the way in which communal healthcare resources are allocated. Second, within the UK’s National Health Service, healthcare is ostensibly not a market resource; thus, permitting crowdfunding introduces market norms that could commodify healthcare. Third, pressures inherent to receiving funds from external parties may threaten the ability of patients-cum-recipients to voluntarily consent to treatment. We conclude that while crowdfunding itself is not unethical, its use can have unforeseen consequences that may influence conceptions of healthcare and how it is delivered.
- allocation of health care resources
- decision-making
- informed consent
- ethics
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Spatially exploring the intersection of socioeconomic status and Canadian cancer-related medical crowdfunding campaigns
- Appealing to the crowd: ethical justifications in Canadian medical crowdfunding campaigns
- Is there room for privacy in medical crowdfunding?
- Medical crowdfunding in China: empirics and ethics
- Crowdfunding for health research: a qualitative evidence synthesis and a pilot programme
- Law, ethics, and emotion: the Charlie Gard case
- Doctors can withdraw life support from baby with rare genetic disorder, says judge
- Is cancer fundraising fuelling quackery?
- Parents of child with rare genetic disorder lose life support appeal
- Why Charlie Gard’s parents should have been the decision-makers about their son’s best interests